Antiangiogenic is also antifibrogenicCompensated cirrhosis: the ideal ground for experimenting antifibrotic drugsReferencesdoi:10.1002/9781444393989.ch21Massimo PinzaniWiley‐BlackwellAntifibrotic Drugs. Pinzani,M. Portal Hypertension V:Proceedings of the Fifth Baveno International Consensus Workshop . 2011
A high throughput screen was performed to discover inhibitors of LARP6 binding to 5′SL, as potential antifibrotic drugs. The screen yielded one compound (C9) which was able to dissociate LARP6 from 5′ SL RNA in vitro and to inactivate the binding of endogenous LARP6 in cells. Treatment ...
11 The applicability of these data to COVID-19 depends on the rapidity of action of antifibrotic drugs and their introduction before severe acute lung injury has supervened (ie, before assisted ventilation). In IPF, acute exacerbations have an almost uniformly poor outcome. This phenotype has ...
Nintedanib is another drug whose efficacy in the treatment of IPF has been confirmed by clinical trials, and both these drugs have recently been approved by the FDA. However, the efficacy of both drugs in severe IPF and the optimal length of therapy remain unknown. Based on the balance of ...
Improvement of diagnostic measures and novel drugs may provide the basis for more successful therapeutic approaches in the future.doi:info:doi/10.1586/17469872.2.2.203Thorsten M OlskiNicolas HunzelmannExpert Review of DermatologyOlski TM, Hunzelmann N. Immunosuppressive and antifibrotic therapy of ...
Background: Fatigue is a common complaint in patients with idiopathic pulmonary fibrosis (IPF) and has been reported in a considerable percentage of patients. Fatigue is also a registered side effect of pirfenidone, one of two approved antifibrotic drugs. The Fatigue Assessment Scale (FAS) was ...
Future clinical trials using a combination of these drugs should be considered during the active phase of PD, given the early evidence of benefit in both in vitro and in vivo models. Patient summary This report suggests that the combination of a phosphodiesterase type 5 inhibitor and a selective...
therapy,[64]suggesting that periods of treatment alternating with intervals without may suffice to prevent development of cirrhosis. The antifibrotic effect of interferon should be considered in the planning and analysis of studies that combine interferon or pegylated interferon with other antiviral drugs....
Inhibition of collagen type I synthesis on the transcriptional level might be more effective than attempting to treat the consequences of collagen overproduction, which is the aim of some other drugs. Based on its mode of action, halofuginone has the potential to be used for treatment ...
Therefore, the influence of liver drug enzyme activity on drugs should be further considered. The metabolism and excretion mechanism of AKF-PD in rats was studied by substance balance and corresponding mechanism, in order to provide theoretical reference for further study of AKF-PD. Data Sharing ...